長澤先生、腎臓って結局どう診ればいいですか？

出版社： 羊土社
著者：
発行日： 2022-10-01
分野： 臨床医学：内科  >  腎臓
ISBN： 9784758123945
電子書籍版： 2022-10-01 （第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,960 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

腎臓病患者の血圧・血糖管理は？CKDの食事指導は？血液透析導入のタイミングは？腎臓病の治療指針はたくさんあるけど，結局どう診ればいいですか？そんな悩みを全て解決する，超具体的な腎臓の診かた教えます！

目次

  • §1　高血圧と腎臓
    　　　降圧の目標／薬物治療の実際／血圧の下限／ SGLT2 阻害薬の登場
    §2　高カリウム血症のマネージメント
    　　　本当にRAA系が必要な患者か考えよう／偽物の高カリウム血症に注意／
    　　　緊急でのマネージメント／慢性期のKのマネージメント
    §3　最近の減塩
    　　　塩と血圧の関係／減塩の第一歩は血圧測定から／減塩がうまくいっているかを
    　　　どうチェックする？／代替塩をどう捉えるか？／飲水励行をどう捉えるか？
    §4　CKDの食事指導
    　 「腎臓病といえば低たんぱく食」の考えは古い／カリウム摂取の考え方／
    　　　リンについてはどうする？
    §5　血糖と腎臓
    　　　糖尿病の歴史／糖尿病治療の目標は？／具体的な治療／
    　　　SGLT2阻害薬かGLP-1受容体作動薬か？
    §6　尿タンパクの捉え方
    　　　検尿の重要性／原疾患を意識しよう
    §7　腎性貧血の治療
    　　　腎性貧血治療の歴史的背景／腎性貧血の診断／治療の実際／
    　　　貧血がよくならないときにどうするか？
    §8　尿酸と腎臓
    　　　何のために尿酸を下げるか？／重み付けをして診療をしよう／具体的な処方は？／
    　　　抗酸化作用は？
    §9　造影剤腎症
    　　　実際のリスク管理／本当はどのくらいの頻度で造影剤腎症が起こるか？
    §10　薬剤性腎障害
    　　　薬剤性腎障害の歴史的経緯／日常臨床上注意する薬
    §11　急性腎障害
    　　　AKIからCKDになることが問題／AKIは防ぎえるか？／AKIの診断基準／
    　　　RRTのタイミング／RRTからの離脱への道筋／バイオマーカーや治療法はあるか？
    §12　急速進行性糸球体腎炎の捉え方
    　　　日常臨床に潜むRPGN／RPGNの疫学／治療について／治療強度はどうするか？／
    　　　抗GBM糸球体腎炎はどうする？／診断は大丈夫？
    §13　IgA腎症
    　　　本邦におけるIgA腎症の疫学／非専門医がIgA腎症発見のためにするべきこと／
    　　　IgA腎症の治療の歴史
    §14　ネフローゼ症候群
    　　　ネフローゼ症候群の診断／ネフローゼ症候群の疫学／ネフローゼ症候群の診療に
    　　　腎生検は必要か？／治療について／再発についてどうするか？
    §15　常染色体優性多発性囊胞腎
    　　　疾患概念／ADPKDの合併症／ADPKDの診断／遺伝子検査まで必要？／
    　　　トルバプタンの実際の使用／囊胞感染のときにどうするか？／ ADPKDにまつわるQ&A
    §16　腎生検について
    　　　診断面から考える腎生検の重要性／腎生検の方針／
    　　　出血量と合併症に関係はあるか？／実臨床に落とし込むには
    §17　ベストな血液透析導入のタイミング
    　　　どのような患者が透析導入になるか？／何をもってよい血液透析導入とするか？／
    　　　いきなり週3回の透析がベストか？

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 高血圧と腎臓

P.21 掲載の参考文献
1) 「高血圧治療ガイドライン 2019」 (日本高血圧学会高血圧治療ガイドライン作成委員会/編), 日本高血圧学会, 2019
 
2) 「原発性アルドステロン症ガイドライン 2021」 (日本内分泌学会/監, 日本内分泌学会「原発性アルドステロン症診療ガイドライン策定と診療水準向上」委員会/編), 診断と治療社, 2021
 
3) Ferreira JP, et al : Abnormalities of Potassium in Heart Failure : JACC State-of-the-Art Review. J Am Coll Cardiol, 75 : 2836-2850, 2020 (PMID : 32498812)
 
4) Fu EL, et al : Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes : A Nationwide Study. J Am Soc Nephrol, 32 : 424-435, 2021 (PMID : 33372009)
 
5) Bhandari S, et al : Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease : the STOP-ACEi trial. Nephrol Dial Transplant, 31 : 255-261, 2016 (PMID : 26429974)
 
6) Wright JT Jr, et al : A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 373 : 2103-2116, 2015 (PMID : 26551272)
 

2 高カリウム血症のマネージメント

P.32 掲載の参考文献
1) Acker CG, et al : Hyperkalemia in hospitalized patients : causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med, 158 : 917-924, 1998 (PMID : 9570179)
 
2) Montague BT, et al : Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol, 3 : 324-330, 2008 (PMID : 18235147)
 
3) McNicholas BA, et al : Treatment of Hyperkalemia With a Low-Dose Insulin Protocol Is Effective and Results in Reduced Hypoglycemia. Kidney Int Rep, 3 : 328-336, 2018 (PMID : 29725636)
 
4) Clase CM, et al : Potassium homeostasis and management of dyskalemia in kidney diseases : conclusions from a Kidney Disease : Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int, 97 : 42-61, 2020 (PMID : 31706619)
 
5) Moussavi K, et al : Management of Hyperkalemia With Insulin and Glucose : Pearls for the Emergency Clinician. J Emerg Med, 57 : 36-42, 2019 (PMID : 31084947)
 
6) Alexander WD, et al : The urinary sodium: potassium ratio and response to diuretics in resistant oedema. Postgrad Med J, 53 : 117-121, 1977 (PMID : 323834)
 
7) Hayes CP Jr, et al : An extravenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Physicians, 80 : 207-216, 1967 (PMID : 6082243)
 
8) Sandle GI, et al : Enhanced rectal potassium secretion in chronic renal insufficiency : evidence for large intestinal potassium adaptation in man. Clin Sci (Lond), 71 : 393-401, 1986 (PMID : 3757437)
 
9) Panese S, et al : Mechanism of enhanced transcellular potassium-secretion in man with chronic renal failure. Kidney Int, 31 : 1377-1382, 1987 (PMID : 3613409)
 
10) Sandle GI, et al : Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis. Clin Sci (Lond), 73 : 247-252, 1987 (PMID : 3652631)
 
11) Mathialahan T & Sandle GI : Dietary potassium and laxatives as regulators of colonic potassium secretion in end-stage renal disease. Nephrol Dial Transplant, 18 : 341-347, 2003 (PMID : 12543890)
 
12) Sumida K, et al : Laxative Use and Risk of Dyskalemia in Patients with Advanced CKD Transitioning to Dialysis. J Am Soc Nephrol : doi : 10.1681/ASN.2020081120, 2021 (PMID : 33547216)
 
13) Sussman EJ, et al : Let Them Eat Healthy : Can Emerging Potassium Binders Help Overcome Dietary Potassium Restrictions in Chronic Kidney Disease? J Ren Nutr, 30 : 475-483, 2020 (PMID : 32147285)
 
14) Ramos CI, et al : Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? Nephrol Dial Transplant, 36 : 2049-2057, 2021 (PMID : 33247727)
 
15) Sussman EJ, et al : Let Them Eat Healthy : Can Emerging Potassium Binders Help Overcome Dietary Potassium Restrictions in Chronic Kidney Disease? J Ren Nutr, 30 : 475-483, 2020 (PMID : 32147285)
 
16) Kanda E, et al : Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan. Kidney Med, 2 : 742-752.e1, 2020 (PMID : 33319198)
 
17) Matsue Y, et al : Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. J Am Coll Cardiol, 69 : 3042-3051, 2017 (PMID : 28641794)
 
18) He X, et al : Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction. ESC Heart Fail, 8 : 3248-3256, 2021 (PMID : 34076960)
 
19) Faselis C, et al : Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. Am J Med, 134 : 797-804, 2021 (PMID : 33359271)
 
20) Eshaghian S, et al : Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol, 97 : 1759-1764, 2006 (PMID : 16765130)
 
21) Ahmed A, et al : Heart failure, chronic diuretic use, and increase in mortality and hospitalization : an observational study using propensity score methods. Eur Heart J, 27 : 1431-1439, 2006 (PMID : 16709595)
 
22) Masuyama T, et al : Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J, 76 : 833-842, 2012 (PMID : 22451450)
 
23) Kasama S, et al : Comparative effects of long and short-acting loop diuretics on mortality in patients with chronic heart failure. Int J Cardiol, 244 : 242-244, 2017 (PMID : 28645802)
 
24) Cosin J & Diez J : Torasemide in chronic heart failure : results of the TORIC study. Eur J Heart Fail, 4 : 507-513, 2002 (PMID : 12167392)
 

3 最近の減塩

P.40 掲載の参考文献
1) 「世界一シンプルで科学的に証明された究極の食事」 (津川友介/著), 東洋経済新報社, 2018
 
1) 「Classics in Arterial Hypertension」 (Arthur Ruskin, eds), Charles Thomas, 1956
 
2) Kempner, W. Treatment of kidney disease and hypertensive vascular disease with rice diet. N Carolina Med. J. 5 : 125-133, 1,944
 
3) Mancilha-Carvalho JJ, et al : Blood pressure and electrolyte excretion in the Yanomamo Indians, an isolated population. J Hum Hypertens, 3 : 309-314, 1989 (PMID : 2810327)
 
4) Elliott P, et al : The INTERSALT study : results for 24 hour sodium and potassium, by age and sex. INTERSALT Co-operative Research Group. J Hum Hypertens, 3 : 323-330, 1989 (PMID : 2810328)
 
5) Neal B, et al : Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med, 385 : 1067-1077, 2021 (PMID : 34459569)
 
6) Sacks FM, et al : Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med, 344 : 3-10, 2001 (PMID : 11136953)
 
7) Iso H, et al : Community-based education classes for hypertension control. A 1.5-year randomized controlled trial. Hypertension, 27 : 968-974, 1996 (PMID : 8613276)
 
8) Uechi K, et al : Advantage of multiple spot urine collections for estimating daily sodium excretion : comparison with two 24-h urine collections as reference. J Hypertens, 34 : 204-214, 2016 (PMID : 26599218)
 
9) Stamler J, et al : Relation of Dietary Sodium (Salt) to Blood Pressure and Its Possible Modulation by Other Dietary Factors : The INTERMAP Study. Hypertension, 71 : 631-637, 2018 (PMID : 29507099)
 
10) Higo Y, et al : Association of the spot urine sodium-to-potassium ratio with blood pressure is independent of urinary Na and K levels : The Nagahama study. Hypertens Res, 42 : 1624-1630, 2019 (PMID : 31182861)
 
11) Averill MM, et al : Spot Urine Sodium-to-Potassium Ratio Is a Predictor of Stroke. Stroke, 50 : 321-327, 2019 (PMID : 30661503)
 
12) Okada E, et al : Dietary sodium : potassium ratio and CVD risk factors among Japanese adults : a retrospective cross-sectional study of pooled data from the National Health and Nutrition Survey, 2003-2017. Br J Nutr, 125 : 79-91, 2021 (PMID : 32674745)
 
13) Ogata S, et al : A multiple 24-hour urine collection study indicates that kidney function decline is related to urinary sodium and potassium excretion in patients with chronic kidney disease. Kidney Int, 101 : 164-173, 2022 (PMID : 34774553)
 
14) Ma Y, et al : 24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk. N Engl J Med, 386 : 252-263, 2022 (PMID : 34767706)
 
15) Ellison DH & Welling P : Insights into Salt Handling and Blood Pressure. N Engl J Med, 385 : 1981-1993, 2021 (PMID : 34788509)
 
16) 「尿路結石症診療ガイドライン 第2版」 (日本泌尿器科学会/日本泌尿器内視鏡学会/日本尿路結石症学会/編), 金原出版, 2013
 
17) Clark WF, et al : Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease : The CKD WIT Randomized Clinical Trial. JAMA, 319 : 1870-1879, 2018 (PMID : 29801012)
 
18) Stenvinkel P, et al : Hibernating bears (Ursidae) : metabolic magicians of definite interest for the nephrologist. Kidney Int, 83 : 207-212, 2013 (PMID : 23254895)
 
19) Rakova N, et al : Increased salt consumption induces body water conservation and decreases fluid intake. J Clin Invest, 127 : 1932-1943, 2017 (PMID : 28414302)
 
20) Kitada K, et al : High salt intake reprioritizes osmolyte and energy metabolism for body fluid conservation. J Clin Invest, 127 : 1944-1959, 2017 (PMID : 28414295)
 
21) Wilck N, et al : Salt-responsive gut commensal modulates TH17 axis and disease. Nature, 551 : 585-589, 2017 (PMID : 29143823)
 
22) Chen L, et al : Modest Sodium Reduction Increases Circulating Short-Chain Fatty Acids in Untreated Hypertensives : A Randomized, Double-Blind, Placebo-Controlled Trial. Hypertension, 76 : 73-79, 2020 (PMID : 32475312)
 

4 CKDの食事指導

P.51 掲載の参考文献
1) 厚生労働省 : 日本人の食事摂取基準 (2020年版) https://www.mhlw.go.jp/content/10904750/000586553.pdf
 
1) 「ニッポン人の西洋料理」 (村上信夫/著), 光文社, 2003
 
2) 「エビデンスに基づく CKD診療ガイドライン 2018」 (日本腎臓学会/編), 東京医学社, 2018
 
3) 山縣邦弘, 他 : CKDステージ G3b～5 診療ガイドライン 2017 (2015 追補版). 日本腎臓学会誌, 59 : 1093-1216, 2017 https://cdn.jsn.or.jp/data/ckd3b-5-2017.pdf
 
4) 鈴木芳樹, 他 : サルコペニア・フレイルを合併した保存期CKDの食事療法の提言. 日本腎臓学会誌, 61 : 525-556, 2019 https://jsn.or.jp/journal/document/61_5/525-555.pdf
 
5) 厚生労働省 : 令和元年国民健康・栄養調査報告 https://www.mhlw.go.jp/content/000710991.pdf
 
6) 「慢性腎臓病に対する食事療法基準 2014年版」 (日本腎臓学会/編), 東京医学社, 2014 https://cdn.jsn.or.jp/guideline/pdf/CKD-Dietaryrecommendations2014.pdf
 
7) 「慢性腎臓病 生活・食事指導マニュアル～栄養指導実践編～」 (日本腎臓学会/編), 東京医学社, 2015
 
8) Isakova T, et al : Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79 : 1370-1378, 2011 (PMID : 21389978)
 
9) Nakano C, et al : Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol, 7 : 810-819, 2012 (PMID : 22362065)
 
10) Parker BD, et al : The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease : the Heart and Soul Study. Ann Intern Med, 152 : 640-648, 2010 (PMID : 20479029)
 
11) Fliser D, et al : Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease : the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol, 18 : 2600-2608, 2007 (PMID : 17656479)
 

5 血糖と腎臓

P.67 掲載の参考文献
1) 「糖尿病診療ガイド2022-23」 (日本糖尿病学会/編著), 文光堂, 2022
 
2) 長與又郎 : 夏目漱石氏剖檢 (標本供覧). 日本消化機病学会雑誌, 16 : 105-117, 1917
 
3) 長與又郎 : 糖尿病の3例, 殊に膵臓および腎臓の変化. 治療及処方, 88 : 155-183, 1927
 
4) 和久金蔵 : 糖尿病における腎系球体の変化について (独文), 日本病理学会々誌, 18 : 413, 1928
 
5) Kimmelstiel P & Wilson C : Intercapillary Lesions in the Glomeruli of the Kidney. Am J Pathol, 12 : 83-98.7, 1936 (PMID : 19970254)
 
6) von Mering J, Minkowski O : Diabetes mellitus nach Pankreasextirpation. Zentralbl Klin Med. 10 : 394-395, 1889
 
7) Banting FG, et al : Pancreatic Extracts in the Treatment of Diabetes Mellitus. Can Med Assoc J, 12 : 141-146, 1922 (PMID : 20314060)
 
8) 佐藤基, 他 : 膵臓ノ内分泌ニ關スル研究. 日本内科学会雑誌, 9 : 327-334, 1921
 
9) Nathan DM, et al : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 329 : 977-986, 1993 (PMID : 8366922)
 
10) The absence of a glycemic threshold for the development of long-term complications : the perspective of the Diabetes Control and Complications Trial. Diabetes, 45 : 1289-1298, 1996 (PMID : 8826962)
 
11) Ohkubo Y, et al : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract, 28 : 103-117, 1995 (PMID : 7587918)
 
12) Ueki K, et al : Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int, 99 : 256-266, 2021 (PMID : 32891604)
 
13) The Epidemiology of Diabetes Interventions and Complications (EDIC) Study : Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy : the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA, 290 : 2159-2167, 2003 (PMID : 14570951)
 
14) Holman RR, et al : 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 359 : 1577-1589, 2008 (PMID : 18784090)
 
15) Du X, et al : Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation : results of the ADVANCE study. Eur Heart J, 30 : 1128-1135, 2009 (PMID : 19282274)
 
16) Duckworth W, et al : Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 360 : 129-139, 2009 (PMID : 19092145)
 
17) Miller ME, et al : Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care, 37 : 634-643, 2014 (PMID : 24170759)
 
18) Ueki K, et al : Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3) : an open-label, randomised controlled trial. Lancet Diabetes Endocrinol, 5 : 951-964, 2017 (PMID : 29079252)
 
19) Buse JB, et al : 2019 update to : Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 63 : 221-228, 2020 (PMID : 31853556)
 
20) American Diabetes Association : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2020. Diabetes Care, 43 : S98-S110, 2020 (PMID : 31862752)
 
21) Stratton IM, et al : Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : prospective observational study. BMJ, 321 : 405-412, 2000 (PMID : 10938048)
 
22) Karter AJ, et al : Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use. JAMA Intern Med, 177 : 1461-1470, 2017 (PMID : 28828479)
PubMed
23) Conan PL, et al : [Hypoglycemic coma and co-trimoxazole in a nondiabetic patient]. Med Mal Infect, 46 : 236-237, 2016 (PMID : 27039069)
 
24) 松岡有子, 他 : 糖尿病治療薬による重症低血糖-10年間に当院救急受診した患者の解析より-. 糖尿病, 64 : 155-162, 2021
 
25) 梅津亮冴, 他 : 日本国内の有害事象自発報告データベース (JADER) を用いたデータマイニングによる経口血糖降下薬と低血糖症との関連性の評価. YAKUGAKU ZASSHI, 134 : 299-304, 2014
Medical*Online
26) Uemura F, et al : Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring. Sci Rep, 11 : 4875, 2021 (PMID : 33649395)
 
27) Hougen I, et al : Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin : a population-based real-world study. BMJ Open Diabetes Res Care, 9 : doi : 10.1136/bmjdrc-2021-002352, 2021 (PMID : 34969692)
 
28) Zullo AR, et al : Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults. J Am Geriatr Soc, 69 : 2923-2930, 2021 (PMID : 34291453)
 
29) Mattishent K & Loke YK : Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents : a systematic review and meta-analysis. Diabetes Obes Metab, 18 : 135-141, 2016 (PMID : 26446922)
 
30) Xu Y, et al : GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes. Kidney Int, 101 : 360-368, 2022 (PMID : 34826514)
 
31) Marso SP, et al : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 375 : 311-322, 2016 (PMID : 27295427)
 
32) Marso SP, et al : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 375 : 1834-1844, 2016 (PMID : 27633186)
 
33) Tuttle KR, et al : Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7) : a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol, 6 : 605-617, 2018 (PMID : 29910024)
 
34) Gerstein HC, et al : Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) : a double-blind, randomised placebo-controlled trial. Lancet, 394 : 121-130, 2019 (PMID : 31189511)
 
35) Lam CSP, et al : Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes : Exploratory Analysis of the AMPLITUDE-O Trial. Circulation, 145 : 565-574, 2022 (PMID : 34775781)
 
36) Kanie T, et al : Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease : a network meta-analysis. Cochrane Database Syst Rev, 10 : CD013650, 2021 (PMID : 34693515)
 
37) 「エビデンスに基づく CKD診療ガイドライン 2018」 (日本腎臓学会/編), 東京医学社, 2018
 
38) 山縣邦弘, 他 : CKDステージ G3b ～ 5 診療ガイドライン 2017 (2015 追補版). 日本腎臓学会誌, 59 : 1093-1216, 2017
 
39) 日本糖尿病・生活習慣病ヒューマンデータ学会 : 糖尿病標準診療マニュアル 2022 http://human-data.or.jp
 

6 尿タンパクの捉え方

P.77 掲載の参考文献
1) 斉藤博 : 『ヒポクラテス全集』における尿に関する記述について. 日泌尿会誌, 97 : 10-19, 2006
 
2) 伊藤喜久 : 尿蛋白臨床研究・検査. 生物理化学, 41 : 325-328, 1997
Medical*Online
3) 川崎幸彦 : 学校検尿システムの歩み-その有用性と問題点-. 小児保健研究, 74 : 59-64, 2015
 
4) 日本腎臓学会 : 一般臨床医 (プライマリケア) のための検尿の考え方・進め方. 2003 https://jsn.or.jp/medic/academicinfo/sbook/kennyou-index.php
 
5) 「CKD診療ガイド 2012」 (日本腎臓学会/編), 東京医学社, 2012
 
6) Iseki K, et al : Proteinuria and the risk of developing end-stage renal disease. Kidney Int, 63 : 1468-1474, 2003 (PMID : 12631363)
 
7) Okubo R, et al : Cost-effectiveness of mass screening for dipstick hematuria in Japan. Clin Exp Nephrol, 26 : 398-412, 2022 (PMID : 35000032)
 
8) Matsushita K, et al : Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts : a collaborative meta-analysis. Lancet, 375 : 2073-2081, 2010 (PMID : 20483451)
 
9) Nakayama M, et al : Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy : the Gonryo study. Hypertens Res, 34 : 1106-1110, 2011 (PMID : 21796127)
 
10) Araki S, et al : Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes, 54 : 2983-2987, 2005 (PMID : 16186402)
 
11) Konta T, et al : Clinical utility of trace proteinuria for microalbuminuria screening in the general population. Clin Exp Nephrol, 11 : 51-55, 2007 (PMID : 17384998)
 

7 腎性貧血の治療

P.87 掲載の参考文献
1) Goldwasser E & Kung CK : Purification of erythropoietin. Proc Natl Acad Sci U S A, 68 : 697-698, 1971 (PMID : 5279510)
 
2) Miyake T, et al : Purification of human erythropoietin. J Biol Chem, 252 : 5558-5564, 1977 (PMID : 18467)
 
3) Jacobs K, et al : Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature, 313 : 806-810, 1985 (PMID : 3838366)
 
4) Semenza GL, et al : Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci U S A, 88 : 5680-5684, 1991 (PMID : 2062846)
 
5) Suzuki N, et al : Use of gene-manipulated mice in the study of erythropoietin gene expression. Methods Enzymol, 435 : 157-177, 2007 (PMID : 17998054)
 
6) 日本透析医会, 他 : 透析施設における標準的な透析操作と感染予防に関するガイドライン (五訂版). 2020 http://www.touseki-ikai.or.jp/htm/05_publish/doc_m_and_g/20200430_infection%20control_guideline.pdf
 
7) 吉原秀高, 他 : 平成2年度大阪府下慢性腎不全患者の実態調査. 大阪透析研会誌, 9 : 289-294, 1991
Medical*Online
8) Hepatitis in dialysis units. Br Med J, 4 : 255-256, 1970 (PMID : 5475840)
 
9) Polakoff S, et al : Hepatitis in dialysis units in the United Kingdom. Br Med J, 3 : 94-99, 1972 (PMID : 4625220)
 
10) Blumberg A & Giger K : Hepatitis in hemodialysis units. N Engl J Med, 283 : 657-658, 1970 (PMID : 5450643)
 
11) Marmion BP, et al : Dialysis-associated hepatitis in Edinburgh ; 1969-1978. Rev Infect Dis, 4 : 619-637, 1982 (PMID : 6812192)
 
12) Macdougall IC : Anaemia and chronic renal failure. Medicine, 43 : 474-477, 2015 https://www.medicinejournal.co.uk/article/S1357-3039 (15) 00120-6/ppt
 
13) Sofue T, et al : Prevalence of anemia in patients with chronic kidney disease in Japan : A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One, 15 : e0236132, 2020 (PMID : 32687544)
 
14) Thomas MC, et al : Unrecognized anemia in patients with diabetes : a cross-sectional survey. Diabetes Care, 26 : 1164-1169, 2003 (PMID : 12663591)
 
15) Guedes M, et al : Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. J Am Soc Nephrol, 32 : 2020-2030, 2021 (PMID : 34244326)
PubMed
16) 日本透析医学会 : 2015年版 日本透析医学会 慢性腎臓病患者における腎性貧血治療のガイドライン. 日透析医会誌, 49 : 89-158, 2016
 
17) 「エビデンスに基づくCKD診療ガイドライン 2018」 (日本腎臓学会/編), 東京医学社, 2018
 
18) Besarab A, et al : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med, 339 : 584-590, 1998 (PMID : 9718377)
 
19) Drueke TB, et al : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med, 355 : 2071-2084, 2006 (PMID : 17108342)
 
20) Singh AK, et al : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med, 355 : 2085-2098, 2006 (PMID : 17108343)
 
21) Pfeffer MA, et al : A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med, 361 : 2019-2032, 2009 (PMID : 19880844)
 
22) Inoue M, et al : Diabetes mellitus and the risk of cancer : results from a large-scale population-based cohort study in Japan. Arch Intern Med, 166 : 1871-1877, 2006 (PMID : 17000944)
 
23) 根木茂雄, 他 : 透析患者と悪性腫瘍. 日腎会誌, 59 : 610-614, 2017
 
24) 海津嘉蔵, 他 : わが国の透析患者における癌の疫学と現状について. 透析会誌, 50 : 79-80, 2017
 
25) Hayashi T, et al : Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. Clin Exp Nephrol, 25 : 110-119, 2021 (PMID : 32949295)
 
26) Tsuruya K, et al : Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease : A pooled analysis of individual patient-level data from clinical trials. Nephrology (Carlton), 22 : 769-775, 2017 (PMID : 27312361)
 
27) Ino J, et al : Early responsiveness to continuous erythropoietin receptor activator predicts renal prognosis and is determined by a novel antioxidative marker in non-dialysis chronic kidney disease : a prospective, observational, single-center study. Clin Exp Nephrol, 24 : 590-597, 2020 (PMID : 32185544)
 
28) Lenga I, et al : Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol, 2 : 688-693, 2007 (PMID : 17699483)
 
29) Icardi A, et al : Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency : the potential role of inflammation. Nephrol Dial Transplant, 28 : 1672-1679, 2013 (PMID : 23468534)
 
30) 「亜鉛欠乏症の診療指針 2018」 (日本臨床栄養学会/編), 日本臨床栄養学会, 2018
 
31) 中野素子, 他 : 銅欠乏による汎血球減少症とESA 療法低反応性を呈した維持血液透析患者の1例. 日透析医会誌, 47 : 85-90, 2014
 
32) Tanaka T, et al : Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease : a post-marketing surveillance study in Japan. Clin Exp Nephrol, 23 : 231-243, 2019 (PMID : 30182223)
 
33) Hayashi T, et al : Darbepoetin Alfa in Patients with Advanced CKD without Diabetes : Randomized, Controlled Trial. Clin J Am Soc Nephrol, 15 : 608-615, 2020 (PMID : 32245781)
 
34) Imai E, et al : Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). Clin Exp Nephrol, 20 : 71-76, 2016 (PMID : 26081567)
 

8 尿酸と腎臓

P.96 掲載の参考文献
1) Kuwabara M, et al : Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res, 37 : 785-789, 2014 (PMID : 24671018)
PubMed
2) Perez-Ruiz F, et al : Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. Rheumatol Int, 35 : 1519-1524, 2015 (PMID : 25763991)
 
3) 「動脈硬化性疾患予防ガイドライン 2017年版」 (日本動脈硬化学会/編), 日本動脈硬化学会, 2017
 
4) 「高尿酸血症・痛風の治療ガイドライン 第3版」 (日本痛風・核酸代謝学会/編), 診断と治療社, 2018
 
5) 「エビデンスに基づくCKD診療ガイドライン 2018」 (日本腎臓学会/編), 東京医学社, 2018
 
6) 「進化医学 人への進化が生んだ疾患」 (井村裕夫/著), 羊土社, 2012
 
7) Sesso HD, et al : Vitamins E and C in the prevention of cardiovascular disease in men : the Physicians' Health Study II randomized controlled trial. JAMA, 300 : 2123-2133, 2008 (PMID : 18997197)
 
8) Rumbold AR, et al : Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med, 354 : 1796-1806, 2006 (PMID : 16641396)
 
9) Miller ER 3rd, et al : Meta-analysis : high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med, 142 : 37-46, 2005 (PMID : 15537682)
 

9 造影剤腎症

P.104 掲載の参考文献
1) 「UBER EINE NEUE -ART VON STRAHLEN」 (Rontgen WC, ed), Springer, 1895 https://www.xtal.iqfr.csic.es/Cristalografia/archivos_10/Uber_eine_neue_art_von_strahlen_ocr.pdf
 
2) Fifty Years of X-Rays. Nature, 156 : 531, 1945 https://www.nature.com/articles/156531a0.pdf
 
3) 梅宮清 : CT・MRIの地域偏在と採算性に関する研究-稼働実態調査に基づく分析-. 商大ビジネスレビュー, 1 : 23-46, 2016
 
4) Osborne ED, et al : Landmark article Feb 10, 1923 : Roentgenography of urinary tract during excretion of sodium iodid. By Earl D. Osborne, Charles G. Sutherland, Albert J. Scholl, Jr. and Leonard G. Rowntree. JAMA, 250 : 2848-2853, 1983 (PMID : 6358545)
 
5) Brooks B : Intra-arterial injection of sodium iodide. JAMA, 82 : 1016-1019, 1924
 
6) Swick M : Darstellung der Niere und Harnwege im Rontgenbild durch Intravenose Einbringung eines neuen Kontraststoffes des Uroselectans. Klin Wochenschr, 8 : 2087-2089, 1929
 
7) Swick M : The discovery of intravenous urography : historical and developmental aspects of the urographic media and their role in other diagnostic and therapeutic areas. Bull N Y Acad Med, 42 : 128-151, 1966 (PMID : 5321904)
 
8) 日本放射線技術学会 : 日本放射線技術史の第一巻 (4.5.2 第二次世界大戦後の各種造影剤と検査法の発達) https://www.jsrt.or.jp/data/pdf/gijutsushi/1kan/04.pdf
 
9) Almen T : Contrast agent design. Some aspects on the synthesis of water soluble contrast agents of low osmolality. J Theor Biol, 24 : 216-226, 1969 (PMID : 5822653)
 
10) McEvoy J, et al : Renal failure after radiological contrast media. Br Med J, 4 : 717-718, 1970 (PMID : 5491257)
 
11) Chamberlain MJ & Gleeson JA : Aortography in the Investigation of Hypertension. Lancet, 1 : 619-621, 1965 (PMID : 14255212)
 
12) Chisholm GD, et al : Primary amyloidosis of the renal pelvis. Br Med J, 1 : 736-738, 1967 (PMID : 6020091)
 
13) Ansell G : A national survey of radiological complications : interim report. Clin Radiol, 19 : 175-191, 1968 (PMID : 5648074)
 
14) Mudge GH : Nephrotoxicity of urographic radiocontrast drugs. Kidney Int, 18 : 540-552, 1980 (PMID : 7007711)
 
15) Barrett BJ : Contrast nephrotoxicity. J Am Soc Nephrol, 5 : 125-137, 1994 (PMID : 7993992)
 
16) Mehran R, et al : A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention : development and initial validation. J Am Coll Cardiol, 44 : 1393-1399, 2004 (PMID : 15464318)
 
17) 日本腎臓学会, 他 : 腎障害患者におけるヨード造影剤使用に関するガイドライン 2018. 日腎会誌, 61 : 933-1081, 2019
 
18) Tsai TT, et al : Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions : insights from the National Cardiovascular Data Registry Cath-PCI Registry. J Am Heart Assoc, 3 : e001380, 2014 (PMID : 25516439)
 
19) Schneider A, et al : Risk of acute kidney injury requiring hemodialysis after contrast-enhanced imaging after traumatic injury : A National Trauma Databank analysis. Surgery, 171 : 1085-1091, 2022 (PMID : 34711427)
 
20) Hinson JS, et al : Risk of Acute Kidney Injury After Intravenous Contrast Media Administration. Ann Emerg Med, 69 : 577-586.e4, 2017 (PMID : 28131489)
 
21) Elias A & Aronson D : Risk of Acute Kidney Injury after Intravenous Contrast Media Administration in Patients with Suspected Pulmonary Embolism : A Propensity-Matched Study. Thromb Haemost, 121 : 800-807, 2021 (PMID : 33302305)
 
22) Goulden R, et al : Association of Intravenous Radiocontrast With Kidney Function : A Regression Discontinuity Analysis. JAMA Intern Med, 181 : 767-774, 2021 (PMID : 33818606)
 
23) Kao TW, et al : Continuous use of metformin in patients receiving contrast medium : what is the evidence? A systematic review and meta-analysis. Eur Radiol : doi : 10.1007/s00330-021-08395-7, 2021 (PMID : 34837099)
 
24) 日本医学放射線学会 : ヨード造影剤ならびにガドリニウム造影剤の急性副作用発症の危険性低減を目的としたステロイド前投薬に関する提言 (2018年11月改訂版). 2018 http://www.radiology.jp/member_info/safty/20181115.html
 
25) ACR Committee on Drugs and Contrast Media : ACR Manual on Contrast Media. 2021 https://www.acr.org/-/media/ACR/files/clinical-resources/contrast_media.pdf
 

10 薬剤性腎障害

P.111 掲載の参考文献
1) 「レジデントのための感染症診療マニュアル 第4版」 (青木眞/著), 医学書院, 2020
 
2) Bailie GR & Neal D : Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp, 3 : 376-386, 1988 (PMID : 3057327)
 
3) Darko W, et al : Mississippi mud no more : cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy, 23 : 643-650, 2003 (PMID : 12741439)
 
4) Rybak M, et al : Therapeutic monitoring of vancomycin in adult patients : a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm, 66 : 82-98, 2009 (PMID : 19106348)
 
5) 成田一衛 : 抗菌薬による腎障害. 日腎会誌, 58 : 1069-1072, 2016
 
6) Inaba I, et al : Risk Evaluation for Acute Kidney Injury Induced by the Concomitant Use of Valacyclovir, Analgesics, and Renin-Angiotensin System Inhibitors : The Detection of Signals of Drug-Drug Interactions. Front Pharmacol, 10 : 874, 2019 (PMID : 31440161)
 
7) Ikuta K, et al : Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury : a nested case-control study. BMJ Open, 11 : e041543, 2021 (PMID : 33589451)
 
8) Wan EYF, et al : Comparative Risks of Nonsteroidal Anti-Inflammatory Drugs on CKD. Clin J Am Soc Nephrol, 16 : 898-907, 2021 (PMID : 33910887)
 
9) 平田純生, 他 : NSAIDs による腎障害- COX-2 阻害薬およびアセトアミノフェンは腎障害を起こすか. 日腎会誌, 58 : 1059-1063, 2016
 
10) Roberts DJ, et al : Angiotensin-Converting Enzyme Inhibitor/Receptor Blocker, Diuretic, or Nonsteroidal Anti-inflammatory Drug Use After Major Surgery and Acute Kidney Injury : A Case-Control Study. J Surg Res, 263 : 34-43, 2021 (PMID : 33631376)
PubMed
11) "西尾康英 : 薬剤性間質性腎障害の最新の知見について. Sysmex Journal Web, 21 (2), 2020 https://www.sysmex.co.jp/products_solutions/library/journal/vol21_no2/20200825.html
 
12) Kitchlu A, et al : Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer : A Population-Based Cohort Study. J Natl Cancer Inst, 111 : 727-736, 2019 (PMID : 30423160)
 
13) 小松康宏, 石井太祐 : 抗がん薬による腎障害. 日腎会誌, 58 : 1064-1068, 2016
 
14) 「がん薬物療法時の腎障害診療ガイドライン 2016」 (日本腎臓学会, 他/編), ライフサイエンス出版, 2016
 
15) 「絶対わかる抗菌薬はじめの一歩」 (矢野晴美/著), p40, 羊土社, 2010
 
16) Finnigan NA & Bashir K : Allergic Interstitial Nephritis : StatPearls [Internet], 2022 (PMID : 29493948)
 
17) Baldwin DS, et al : Renal failure and interstitial nephritis due to penicillin and methicillin. N Engl J Med, 279 : 1245-1252, 1968 (PMID : 4176988)
 
18) Border WA, et al : Antitubular basement-membrane antibodies in methicillin-associated interstitial nephritis. N Engl J Med, 291 : 381-384, 1974 (PMID : 4211170)
 

11 急性腎障害

P.121 掲載の参考文献
1) Teschan PE : Hemodialysis in military casualties. 1955. ASAIO J, 44 : 260-262 ; discussion 259, 1998 (PMID : 9682950)
 
2) 近藤賢 : 泌尿器疾患における腎不全の血液化學的研究. 日泌尿會誌, 47 : 222-225, 1956
 
3) 仁平寛巳 : 急性腎不全の治療-Kolff型人工腎による血液透析法を中心として-. 日腎会誌, 6 : 25-28, 1964
 
4) 石塚栄一, 他 : 悪性腫瘍の術後に発生した急性腎皮質壊死の一例. 日腎会誌, 15 : 91-101, 1973
 
5) Miyamoto Y, et al : Temporal change in characteristics and outcomes of acute kidney injury on renal replacement therapy in intensive care units : analysis of a nationwide administrative database in Japan, 2007-2016. Crit Care, 23 : 172, 2019 (PMID : 31092273)
 
6) Hoste EAJ, et al : Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol, 14 : 607-625, 2018 (PMID : 30135570)
 
7) Ympa YP, et al : Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med, 118 : 827-832, 2005 (PMID : 16084171)
 
8) Hsu RK, et al : Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol, 24 : 37-42, 2013 (PMID : 23222124)
 
9) Hatakeyama Y, et al : Transition from acute kidney injury to chronic kidney disease : a single-centre cohort study. Clin Exp Nephrol, 22 : 1281-1293, 2018 (PMID : 29633059)
 
10) Nagasawa T, et al : A case series of acute renal infarction at a single center in Japan. Clin Exp Nephrol, 20 : 411-415, 2016 (PMID : 26377692)
 
11) Kagaya S, et al : Renal infarct volume and renal function decline in acute and chronic phases. Clin Exp Nephrol, 21 : 1030-1034, 2017 (PMID : 28283850)
 
12) Nagata K, et al : Effects of transient acute kidney injury, persistent acute kidney injury and acute kidney disease on the long-term renal prognosis after an initial acute kidney injury event. Nephrology (Carlton), 26 : 312-318, 2021 (PMID : 33207040)
 
13) Khwaja A : KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 120 : c179-c184, 2012 (PMID : 22890468)
 
14) Macedo E, et al : International Society of Nephrology 0 by 25 Project : Lessons Learned. Ann Nutr Metab, 74 Suppl 3 : 45-50, 2019 (PMID : 31203299)
 
15) Evans L, et al : Surviving Sepsis Campaign : International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med, 49 : e1063-e1143, 2021 (PMID : 34605781)
 
16) 江木盛時, 他 : 日本版敗血症診療ガイドライン 2020 (J-SSCG2020). 日集中医誌 (増刊), 28 : S1-S414, 2021
 
17) Hatakeyama Y, et al : Incidence of acute kidney injury among patients with chronic kidney disease : a single-center retrospective database analysis. Clin Exp Nephrol, 21 : 43-48, 2017 (PMID : 26879775)
 
18) Bellomo R, et al : Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs : the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care, 8 : R204-R212, 2004 (PMID : 15312219)
 
19) Mehta RL, et al : Acute Kidney Injury Network : report of an initiative to improve outcomes in acute kidney injury. Crit Care, 11 : R31, 2007 (PMID : 17331245)
 
20) Khwaja A : KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 120 : c179-c184, 2012 (PMID : 22890468)
 
21) 「AKI (急性腎障害) 診療ガイドライン 2016」 (AKI (急性腎障害) 診療ガイドライン作成委員会/編), 東京医学社, 2016
 
22) Hatakeyama Y, et al : Evaluation of the accuracy of estimated baseline serum creatinine for acute kidney injury diagnosis. Clin Exp Nephrol, 22 : 405-412, 2018 (PMID : 28983757)
 
23) Vinsonneau C, et al : Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome : a multicentre randomised trial. Lancet, 368 : 379-385, 2006 (PMID : 16876666)
 
24) Palevsky PM, et al : Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med, 359 : 7-20, 2008 (PMID : 18492867)
 
25) Bellomo R, et al : Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med, 361 : 1627-1638, 2009 (PMID : 19846848)
 
26) Gaudry S, et al : Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med, 375 : 122-133, 2016 (PMID : 27181456)
 
27) Zarbock A, et al : Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury : The ELAIN Randomized Clinical Trial. JAMA, 315 : 2190-2199, 2016 (PMID : 27209269)
 
28) Barbar SD, et al : Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. N Engl J Med, 379 : 1431-1442, 2018 (PMID : 30304656)
 
29) Bagshaw SM, et al : Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med, 383 : 240-251, 2020 (PMID : 32668114)
 
30) Gaudry S, et al : Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2) : a multicentre, open-label, randomised, controlled trial. Lancet, 397 : 1293-1300, 2021 (PMID : 33812488)
 
31) Maynar Moliner J, et al : Handling continuous renal replacement therapy-related adverse effects in intensive care unit patients : the dialytrauma concept. Blood Purif, 34 : 177-185, 2012 (PMID : 23095418)
 
32) Philipponnet C, et al : Kidney biopsy in the critically ill patient, results of a multicentre retrospective case series. Minerva Anestesiol, 79 : 53-61, 2013 (PMID : 23044736)
 
33) de Chambrun MP, et al : Transvenous Renal Biopsy of Critically Ill Patients : Safety and Diagnostic Yield. Crit Care Med, 47 : 386-392, 2019 (PMID : 30608282)
 

12 急速進行性糸球体腎炎の捉え方

P.137 掲載の参考文献
1) Davies DJ, et al : Segmental necrotising glomerulonephritis with antineutrophil antibody : possible arbovirus aetiology? Br Med J (Clin Res Ed), 285 : 606, 1982 (PMID : 6297657)
 
2) van der Woude FJ, et al : Autoantibodies against neutrophils and monocytes : tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet, 1 : 425-429, 1985 (PMID : 2857806)
 
3) Jennette JC, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum, 37 : 187-192, 1994 (PMID : 8129773)
 
4) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum, 65 : 1-11, 2013 (PMID : 23045170)
 
5) Serra A, et al : Vasculitis affecting the kidney : presentation, histopathology and long-term outcome. Q J Med, 53 : 181-207, 1984 (PMID : 6463195)
 
6) Savage CO, et al : Microscopic polyarteritis : presentation, pathology and prognosis. Q J Med, 56 : 467-483, 1985 (PMID : 4048389)
 
7) Guillevin L, et al : Microscopic polyangiitis : clinical and laboratory findings in eighty-five patients. Arthritis Rheum, 42 : 421-430, 1999 (PMID : 10088763)
 
8) 山縣邦弘, 他 : 急速進行性糸球体腎炎ワーキンググループ. 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎疾患に関する調査研究 平成27年度総括・分担研究報告書, 57-61, 2016 https://mhlw-grants.niph.go.jp/system/files/2019/192051/201911010B_upload/201911010B202005141132533340007.pdf
 
9) Koyama A, et al : A nationwide survey of rapidly progressive glomerulonephritis in Japan : etiology, prognosis and treatment diversity. Clin Exp Nephrol, 13 : 633-650, 2009 (PMID : 19533266)
 
10) 「エビデンスに基づく急速進行性腎炎症候群 (RPGN) 診療ガイドライン 2020」 (厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「難治性腎障害に関する調査研究」班/編), 東京医学社, 2020
 
11) 松尾清一, 他 : 厚生労働省特定疾患進行性腎障害に関する調査研究班報告 急速進行性腎炎症候群の診療指針 第2版. 日腎会誌, 53 : 509-555, 2011
 
12) Mukhtyar C, et al : Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis, 68 : 1827-1832, 2009 (PMID : 19054820)
 
13) Biscetti F, et al : The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). Medicine (Baltimore), 95 : e5506, 2016 (PMID : 27902615)
 
14) Exley AR, et al : Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum, 40 : 371-380, 1997 (PMID : 9041949)
 
15) Hellmich B, et al : EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis : focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis, 66 : 605-617, 2007 (PMID : 17170053)
 
16) Saito A, et al : Remission Induction Therapy with Rituximab for Microscopic Polyangiitis : A Feasibility Study. Tohoku J Exp Med, 242 : 53-62, 2017 (PMID : 28539536)
 
17) Stone JH, et al : Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med, 363 : 221-232, 2010 (PMID : 20647199)
 
18) Nagafuchi H, et al : Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis. Mod Rheumatol, 25 : 603-608, 2015 (PMID : 25496405)
 
19) Furuta S, et al : Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis : A Randomized Clinical Trial. JAMA, 325 : 2178-2187, 2021 (PMID : 34061144)
 
20) 清水芳男, 富野康日己 : 抗糸球体基底膜抗体型腎炎とRPGN. 日腎会誌, 51 : 94-97, 2009
 
21) Hirayama K, et al : Anti-glomerular basement membrane antibody disease in Japan : part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol, 12 : 339-347, 2008 (PMID : 18392773)
 
22) Walsh M, et al : Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med, 382 : 622-631, 2020 (PMID : 32053298)
 
23) Berden AE, et al : Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol, 21 : 1628-1636, 2010 (PMID : 20616173)
 
24) Brix SR, et al : Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int, 94 : 1177-1188, 2018 (PMID : 30385041)
 
25) Nezam D, et al : Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges. J Am Soc Nephrol, 33 : 628-637, 2022 (PMID : 35074934)
 
26) Walsh M, et al : The effects of plasma exchange in patients with ANCA-associated vasculitis : an updated systematic review and meta-analysis. BMJ, 376 : e064604, 2022 (PMID : 35217545)
 
27) Zeng L, et al : Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis : a clinical practice guideline. BMJ, 376 : e064597, 2022 (PMID : 35217581)
 
28) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis, 66 : 222-227, 2007 (PMID : 16901958)
 
29) Sada KE, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther, 16 : R101, 2014 (PMID : 24758294)
 
30) Ojima Y, et al : Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis (AAV) Restricted to the Limbs. Intern Med, 57 : 1301-1308, 2018 (PMID : 29279515)
 
31) 高橋啓, 他 : 血管炎の新しい分類 : 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC2012). 日腎会誌, 56 : 70-79, 2014
 

13 IgA腎症

P.153 掲載の参考文献
1) 「Reports of Medical Cases, selected with a view of illustrating the symptoms and cure of disease by a reference to morbid anatomy. 2 vol. (in 3) 」 (Bright R), Longman, 1827
 
2) Bowman, W. : On the structre and use of the malpighian bodies of the kidney, with observations on the circulation through that gland. Phil. Trans.132 : 57-80, 1842
 
3) 真鍋俊明 : 関連する医学・医療分野の歴史 5 診断病理学. 日内会誌, 91 : 95-99, 2002
 
4) Berger J & Hinglais N : [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris), 74 : 694-695, 1968 (PMID : 4180586)
 
5) Mellors RC, et al : Analytic pathology : histochemical demonstration of antibody localization in tissues, with special reference to the antigenic components of kidney and lung. Lab Invest, 4 : 69-89, 1955 (PMID : 14354905)
 
6) 「IgA 腎症の病態と治療」 (富野康日己/監, 川村哲也, 鈴木祐介/編), 中外医学社, 2019
 
7) 遠藤正之 : IgA 腎症の疫学・症候・予後. 日腎会誌, 50 : 442-447, 2008
 
8) Chauveau D & Droz D : Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol, 104 : 1-5, 1993 (PMID : 8325022)
 
9) Goto M, et al : A scoring system to predict renal outcome in IgA nephropathy : a nationwide 10-year prospective cohort study. Nephrol Dial Transplant, 24 : 3068-3074, 2009 (PMID : 19515800)
 
10) 厚生労働省 : 令和2年簡易生命表の概況 https://www.mhlw.go.jp/toukei/saikin/hw/life/life20/dL/life18-02.pdf
 
11) 厚生労働省 : 第11回健康日本21 (第二次) 推進専門委員会 資料 https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000166296_7.pdf
 
12) Tomino Y, et al : Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. J Clin Lab Anal, 14 : 220-223, 2000 (PMID : 11018800)
 
13) Ieiri N, et al : Impact of annual urine health check-up system to obtain clinical remission in patients with IgA nephropathy. Contrib Nephrol, 157 : 104-108, 2007 (PMID : 17495445)
 
14) 松尾清一, 他 : IgA 腎症診療指針 第3版. 日腎会誌, 53 : 123-135, 2011 https://cdn.jsn.or.jp/jsn_new/iryou/free/kousei/pdf/53_2_123-135.pdf
 
15) Beukhof JR, et al : Toward individual prognosis of IgA nephropathy. Kidney Int, 29 : 549-556, 1986 (PMID : 3702212)
 
16) Bennett WM & Kincaid-Smith P : Macroscopic hematuria in mesangial IgA nephropathy : correlation with glomerular crescents and renal dysfunction. Kidney Int, 23 : 393-400, 1983 (PMID : 6842963)
 
17) Winkenwerder WL : Infection and Hemorrhagic Nephritis. Arch Intern Med (Chic), 56 : 297-326, 1935
 
18) Hayman JM & Martin JW : Acute nephritis : review of 77 cases. Am J Med Sci, 200 : 505, 1940
 
19) 吉本和夫 : 腎炎およびこれと関連ある数種疾患におけるアンチストレプトリジンOの消長について. 最新医学, 11 : 3015-3022, 1956
 
20) 所信五郎 : アンギナ腎炎に対する扁桃腺摘出の意義. 日耳鼻, 41 : 139, 1938
 
21) 高田敦徳 : アンギーナ腎炎に対する扁桃剔出の影響. 日本医事新報, 1452 : 636-638, 1952
 
22) 高橋博子 : 腎炎における扁桃摘出術にツイテの臨床的研究. 日耳鼻, 71 : 353-369, 1968
 
23) Lumio JS : Effect of acute tonsillitis and tonsillectomy on the course of nephritis. Acta Otolaryngol, 42 : 113-124, 1952 (PMID : 14932972)
 
24) Kobayashi Y, et al : Steroid therapy in IgA nephropathy : a prospective pilot study in moderate proteinuric cases. Q J Med, 61 : 935-943, 1986 (PMID : 3628707)
 
25) Kobayashi Y, et al : Effect of corticosteroids on renal function in progressive IgA nephropathy--long-term follow-up study. Nihon Jinzo Gakkai Shi, 30 : 1135-1142, 1988 (PMID : 3216556)
 
26) Kobayashi Y, et al : Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron, 72 : 237-242, 1996 (PMID : 8684533)
 
27) Pozzi C, et al : Corticosteroids in IgA nephropathy : a randomised controlled trial. Lancet, 353 : 883-887, 1999 (PMID : 10093981)
 
28) Hotta O, et al : Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis, 38 : 736-743, 2001 (PMID : 11576876)
 
29) 「IgA 腎症の病態と扁摘パルス療法 第2版」 (堀田修/著), メディカルサイエンスインターナショナル, 2022
 
30) Sato M, et al : Cohort study of advanced IgA nephropathy : efficacy and limitations of corticosteroids with tonsillectomy. Nephron Clin Pract, 93 : c137-c145, 2003 (PMID : 12759582)
 
31) Miyazaki M, et al : A multicenter prospective cohort study of tonsillectomy and steroid therapy in Japanese patients with IgA nephropathy : a 5-year report. Contrib Nephrol, 157 : 94-98, 2007 (PMID : 17495443)
 
32) Komatsu H, et al : Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy : a controlled study. Clin J Am Soc Nephrol, 3 : 1301-1307, 2008 (PMID : 18508946)
 
33) Kawamura T, et al : A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant, 29 : 1546-1553, 2014 (PMID : 24596084)
 
34) Komatsu H, et al : Significance of tonsillectomy combined with steroid pulse therapy for IgA nephropathy with mild proteinuria. Clin Exp Nephrol, 20 : 94-102, 2016 (PMID : 26123429)
 
35) Miyamoto T, et al : Impact of tonsillectomy combined with steroid pulse therapy on immunoglobulin A nephropathy depending on histological classification : a multicenter study. Clin Exp Nephrol, 20 : 50-57, 2016 (PMID : 26055039)
 
36) Hoshino Y, et al : Comparison of oral steroids with tonsillectomy plus steroid pulse therapy in patients with IgA nephropathy. Clin Exp Nephrol, 21 : 617-623, 2017 (PMID : 27549901)
 
37) Hirano K, et al : Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy. JAMA Netw Open, 2 : e194772, 2019 (PMID : 31150076)
 
38) Kumon S, et al : The impact of tonsillectomy combined with steroid pulse therapy in patients with advanced IgA nephropathy and impaired renal function. Clin Exp Nephrol, 24 : 295-306, 2020 (PMID : 31845064)
 
39) Moriyama T, et al : Impact of the number of steroid pulses in tonsillectomy combined with steroid pulse therapy : a nationwide retrospective study in Japan. Clin Exp Nephrol, 25 : 19-27, 2021 (PMID : 32880761)
 
40) Inker LA, et al : Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy : An Individual Participant Meta-analysis. Am J Kidney Dis, 78 : 340-349.e1, 2021 (PMID : 33775708)
 
41) Trimarchi H, et al : IgA nephropathy : " State of the art" : a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first description. Kidney Int, 95 : 750-756, 2019 (PMID : 30904065)
 
42) 花房規男, 他 : わが国の慢性透析療法の現況 (2020年12月31日現在). 日透析医会誌, 54 : 611-657, 2021
 
43) 「エビデンスに基づくIgA 腎症診療ガイドライン 2017」 (丸山彰一/監, 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎障害に関する調査研究班/編), 東京医学社, 2017
 
44) Barratt J & Floege J : SGLT-2 inhibition in IgA nephropathy : the new standard of care? Kidney Int, 100 : 24-26, 2021 (PMID : 33878337)
 

14 ネフローゼ症候群

P.172 掲載の参考文献
1) Muller KF : Korreferet. Morbus Brightii, Verhandl. Deut Path Gesell Merano, 9 : 64-99, 1905
 
2) Munk F : Die nephrosen. Med Klin 12 : 1019-1076, 1916
 
3) Jones DB : Nephrotic glomerulonephritis. Am J Pathol, 33 : 313-329, 1957 (PMID : 13402889)
 
4) Jones DB : Glomerulonephritis. Am J Pathol, 29 : 33-51, 1953 (PMID : 13016781)
 
5) D'Agati VD & Mengel M : The rise of renal pathology in nephrology : structure illuminates function. Am J Kidney Dis, 61 : 1016-1025, 2013 (PMID : 23410654)
 
6) Fahr Th : Pathologische Anatomie des Morbus Brighti. 「Handbuch der Speziellen Pathologischen Anatomie und Histologie Vol 6」 (Henke F & Lubarsh O, eds) pp156-472, Springer, 1925
 
7) 横山仁, 他 : 腎臓病総合レジストリー (J-RBR/J-KDR) の経緯と展望. 日腎会誌, 59 : 1042-1048, 2017
 
8) Omokawa A, et al : Renal biopsy in patients aged 80 years and older : a single-center experience in Japan. Clin Nephrol, 77 : 461-467, 2012 (PMID : 22595388)
 
9) Yokoyama H, et al : Outcomes of primary nephrotic syndrome in elderly Japanese : retrospective analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol, 19 : 496-505, 2015 (PMID : 25230687)
 
10) Chiba Y, et al : Spontaneous remission of minimal change nephrotic syndrome in an elderly man. CEN Case Rep, 10 : 301-307, 2021 (PMID : 33398783)
 
11) 丸山彰一, 秋山真一 : 膜性腎症における自己抗体. 日腎会誌, 56 : 486-492, 2014
 
12) Akiyama S, et al : Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol, 19 : 653-660, 2015 (PMID : 25412738)
 
13) Hihara K, et al : Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy. PLoS One, 11 : e0158154, 2016 (PMID : 27355365)
 
14) Wada T, et al : A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int, 85 : 641-648, 2014 (PMID : 24429394)
 
15) Nakamura J, et al : New selectivity index calculated using protein fraction as a substitute for the conventional selectivity index. Clin Exp Nephrol, 23 : 1196-1201, 2019 (PMID : 31172351)
 
16) Bazzi C, et al : A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int, 58 : 1732-1741, 2000 (PMID : 11012907)
 
17) 「エビデンスに基づくネフローゼ症候群診療ガイドライン 2020」 (厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「難治性腎障害に関する調査研究」班/編) 東京医学社, 2020
 
18) Muso E, et al : Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function. Ther Apher Dial, 26 : 220-228, 2022 (PMID : 34057286)
 
19) Muso E : Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin Exp Nephrol, 18 : 286-290, 2014 (PMID : 24535024)
 
20) Muso E, et al : Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome : evidence from the short-term results from the POLARIS Study. Clin Exp Nephrol, 19 : 379-386, 2015 (PMID : 24934117)
 
21) Nishizawa K, et al : Membranous nephropathy complicated by immune thrombocytopenia treated with low-density lipoprotein apheresis : a case report and literature review. CEN Case Rep, 11 : 43-49, 2022 (PMID : 34287815)
 
22) Kopp JB, et al : Podocytopathies. Nat Rev Dis Primers, 6 : 68, 2020 (PMID : 32792490)
 
24) Dahan K, et al : Rituximab for Severe Membranous Nephropathy : A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol, 28 : 348-358, 2017 (PMID : 27352623)
 
25) Fervenza FC, et al : Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med, 381 : 36-46, 2019 (PMID : 31269364)
 
26) Scolari F, et al : Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy : The RI-CYCLO Randomized Trial. J Am Soc Nephrol : doi : 10.1681/ASN.2020071091, 2021 (PMID : 33649098)
 
27) Katsuno T, et al : Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy : A Single-center Experience. Intern Med, 56 : 1679-1686, 2017 (PMID : 28674357)
 
28) Sugiura H, et al : Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract, 117 : c98-105, 2011 (PMID : 20693810)
 
29) Seitz-Polski B, et al : High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. Clin J Am Soc Nephrol, 14 : 1173-1182, 2019 (PMID : 31340979)
 
30) Seitz-Polski B, et al : Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. J Am Soc Nephrol, 27 : 1517-1533, 2016 (PMID : 26567246)
 
31) Shinzawa M, et al : Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease : a retrospective cohort study. Clin Exp Nephrol, 17 : 839-847, 2013 (PMID : 23512647)
 
32) Shinzawa M, et al : Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease : a retrospective cohort study. Clin J Am Soc Nephrol, 9 : 1040-1048, 2014 (PMID : 24721890)
 
33) Yamamoto R, et al : Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis : the Japan Nephrotic Syndrome Cohort Study. J Nephrol, 35 : 1135-1144, 2022 (PMID : 35366214)
 
34) Ozeki T, et al : Treatment patterns and steroid dose for adult minimal change disease relapses : A retrospective cohort study. PLoS One, 13 : e0199228, 2018 (PMID : 29912938)
 
35) George MD, et al : Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. Ann Intern Med, 173 : 870-878, 2020 (PMID : 32956604)
 
23 Rovin BH, et al : Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int, 100 : 753-779, 2021 (PMID : 34556300)
 

15 常染色体優性多発性嚢胞腎

P.187 掲載の参考文献
1) 「名画で読み解く ハプスブルク家12の物語」 (中野京子/著), 光文社, 2008
 
1) Vilas R, et al : Is the "Habsburg jaw" related to inbreeding? Ann Hum Biol, 46 : 553-561, 2019 (PMID : 31786955)
 
2) Alvarez G, et al : The role of inbreeding in the extinction of a European royal dynasty. PLoS One, 4 : e5174, 2009 (PMID : 19367331)
 
3) Vargas-Poussou R, et al : Genetic investigation of autosomal recessive distal renal tubular acidosis : evidence for early sensorineural hearing loss associated with mutations in the ATP6V0A4 gene. J Am Soc Nephrol, 17 : 1437-1443, 2006 (PMID : 16611712)
 
4) Stover EH, et al : Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence for hearing loss. J Med Genet, 39 : 796-803, 2002 (PMID : 12414817)
 
5) Weisz GM, et al : Skin disease in the Medici family and the illness of Contessina de' Bardi de' Medici : a dermatological puzzle. Int J Dermatol, 53 : 786-788, 2014 (PMID : 24697407)
 
6) Weisz GM, et al : The Medici syndrome : a medico-historical puzzle. Int J Rheum Dis, 13 : 125-131, 2010 (PMID : 20536596)
 
7) Young TL : Molecular genetics of human myopia : an update. Optom Vis Sci, 86 : E8-E22, 2009 (PMID : 19104467)
 
8) 「Museum of Glasses Salerno : History of glasses」https://www.museodellocchialesalerno.it/en/45-storia-en/104-history-of-glasses.html"
 
9) Weisz GM, et al : The ossification diathesis in the Medici family : DISH and other features. Rheumatol Int, 31 : 1649-1652, 2011 (PMID : 21240504)
 
10) Lugli A, et al : [The autopsy of Napoleon Bonaparte : Anatomo-pathological assessment for the bicentenary of the death of Napoleon I on the island of Saint Helena in 1821]. Ann Pathol, 41 : 381-386, 2021 (PMID : 34023091)
 
11) Balat A : Tear drops of kidney : a historical overview of Polycystic Kidney Disease. G Ital Nefrol, 33 Suppl 66 : 33.S66.21, 2016 (PMID : 26913889)
 
12) Walter F : La maladie et la mort d'etienne Bathory, roi de pologne. Aesculape, 24 : 194-202, 1934
 
13) "エビデンスに基づく 多発性嚢胞腎 (PKD) 診療ガイドライン 2014 (松尾清一/監), 東京医学社, 2014 https://cdn.jsn.or.jp/guideline/pdf/PKD_141023.pdf"
 
14) Chauveau D, et al : Intracranial aneurysms in autosomal dominant polycystic kidney disease. Kidney Int, 45 : 1140-1146, 1994 (PMID : 8007584)
 
15) Vlak MH, et al : Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period : a systematic review and meta-analysis. Lancet Neurol, 10 : 626-636, 2011 (PMID : 21641282)
 
16) 「エビデンスに基づく多発性嚢胞腎 (PKD) 診療ガイドライン 2020」〔厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎障害に関する調査研究班/編, 成田一衛/監〕, 東京医学社, 2020 https://jsn.or.jp/academicinfo/report/evidence_PKD_guideline2020.pdf"
 
17) Zhou Z, et al : Is Regular Screening for Intracranial Aneurysm Necessary in Patients with Autosomal Dominant Polycystic Kidney Disease? A Systematic Review and Meta-analysis. Cerebrovasc Dis, 44 : 75-82, 2017 (PMID : 28502970)
 
18) 「エビデンスに基づく多発性嚢胞腎 (PKD) 診療ガイドライン 2014 準拠 多発性嚢胞腎診療ガイド Q&A 改訂第2版」 (堀江重郎/編, 松尾清一/監), 診断と治療社, 2015
 
19) Reed B, et al : Renal ultrasonographic evaluation in children at risk of autosomal dominant polycystic kidney disease. Am J Kidney Dis, 56 : 50-56, 2010 (PMID : 20452711)
 
20) Schrier RW, et al : Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med, 371 : 2255-2266, 2014 (PMID : 25399733)
 
21) Torres VE, et al : Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med, 371 : 2267-2276, 2014 (PMID : 25399731)
 
22) Schrier R, et al : Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease : results of a seven-year prospective randomized study. J Am Soc Nephrol, 13 : 1733-1739, 2002 (PMID : 12089368)
 
23) Klahr S, et al : Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol, 5 : 2037-2047, 1995 (PMID : 7579052)
 
24) Flack JM, et al : Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults : the CARDIA study. Am Heart J, 138 : 486-492, 1999 (PMID : 10467199)
 
25) Lumiaho A, et al : Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. Am J Kidney Dis, 38 : 1208-1216, 2001 (PMID : 11728952)
 
26) Bae KT, et al : Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol, 17 : 374-384, 2022 (PMID : 35217526)
 
27) 「感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版) 」 (日本循環器学会/編), 日本循環器学会, 2018 https://www.j-circ.or.jp/cms/wp-content/uploads/2017/07/JCS2017_nakatani_h.pdf"
 
28) Mizuno H, et al : Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use. PLoS One, 17 : e0264065, 2022 (PMID : 35176098)
 
29) Sakuhara Y, et al : Initial experience with the use of tris-acryl gelatin microspheres for transcatheter arterial embolization for enlarged polycystic liver. Clin Exp Nephrol, 23 : 825-833, 2019 (PMID : 30771042)
 
30) Yoshimoto T, et al : Epidemiological Features of and Screening for Polycystic Kidney Disease in Japan. Ningen Dock International, 6 : 62-68, 2019
 
31) 日本消化器がん検診学会, 超音波検診委員会, 腹部超音波検診判定マニュアルの改訂に関するワーキンググループ : 腹部超音波検診判定マニュアル改訂版 (2021年). 日本消化器がん検診学会雑誌, 60 : 123-181, 2022 https://www.jsgcs.or.jp/files/uploads/manual2021.pdf"
 
32) Sekine A, et al : Genotype-Clinical Correlations in Polycystic Kidney Disease with No Apparent Family History. Am J Nephrol, 49 : 233-240, 2019 (PMID : 30820006)
 
33) Poster D, et al : Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia : a case series. Am J Kidney Dis, 54 : 450-458, 2009 (PMID : 19515475)
PubMed
34) Lanktree MB, et al : Evolving role of genetic testing for the clinical management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant, 34 : 1453-1460, 2019 (PMID : 30165646)
 
35) Chebib FT, et al : A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol, 29 : 2458-2470, 2018 (PMID : 30228150)
 
36) Cornec-Le Gall E, et al : The PROPKD Score : A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol, 27 : 942-951, 2016 (PMID : 26150605)
 
37) Suwabe T, et al : Clinical features of cyst infection and hemorrhage in ADPKD : new diagnostic criteria. Clin Exp Nephrol, 16 : 892-902, 2012 (PMID : 22688273)
 
38) Suwabe T, et al : Intracystic magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease : features of severe cyst infection in a case-control study. BMC Nephrol, 17 : 170, 2016 (PMID : 27829402)
 
39) Pijl JP, et al : 18F-FDG PET/CT in Autosomal Dominant Polycystic Kidney Disease Patients with Suspected Cyst Infection. J Nucl Med, 59 : 1734-1741, 2018 (PMID : 29653972)
 
40) 「レジデントのための感染症診療マニュアル 第4版」 (青木眞/著), 医学書院, 2020
 
41) Hamanoue S, et al : Cyst infection in autosomal dominant polycystic kidney disease : penetration of meropenem into infected cysts. BMC Nephrol, 19 : 272, 2018 (PMID : 30340529)
 
42) Jaisuresh K, et al : Successful conservative treatment of bilateral emphysematous pyelonephritis in autosomal dominant polycystic kidney disease. Indian J Nephrol, 23 : 229-231, 2013 (PMID : 23814427)
 
43) Suwabe T, et al : Cyst infection in autosomal dominant polycystic kidney disease : causative microorganisms and susceptibility to lipid-soluble antibiotics. Eur J Clin Microbiol Infect Dis, 34 : 1369-1379, 2015 (PMID : 25851811)
 
44) Suwabe T : Cyst infection in autosomal dominant polycystic kidney disease : our experience at Toranomon Hospital and future issues. Clin Exp Nephrol, 24 : 748-761, 2020 (PMID : 32700112)
 
45) Kramers BJ, et al : Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD : A Randomized Crossover Trial. Clin J Am Soc Nephrol, 17 : 507-517, 2022 (PMID : 35314480)
 
46) Orth SR, et al : Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int, 54 : 926-931, 1998 (PMID : 9734618)
 
47) Sousa MV, et al : Smoking accelerates renal cystic disease and worsens cardiac phenotype in Pkd1-deficient mice. Sci Rep, 11 : 14443, 2021 (PMID : 34262092)
 
48) McKenzie KA, et al : Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression : a retrospective analysis using the CRISP cohort. BMC Nephrol, 19 : 378, 2018 (PMID : 30591038)
 
49) Weiss AS, et al : Twelve-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation. Clin J Am Soc Nephrol, 4 : 988-995, 2009 (PMID : 19406961)
 
50) Warner G, et al : Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J Am Soc Nephrol, 27 : 1437-1447, 2016 (PMID : 26538633)
 

16 腎生検について

P.195 掲載の参考文献
1) Iversen P & Brun C : Aspiration biopsy of the kidney. Am J Med, 11 : 324-330, 1951 (PMID : 14877837)
 
2) シリーズ/座談会 : 日本の腎臓研究を振り返る. 日腎会誌, 44 : 752-778, 2002
 
3) 木下康民, 他 : 腎炎の治癒判定. 綜合臨床, 13 : 2026, 1964
 
4) Hamano T, et al : Biopsy-proven CKD etiology and outcomes : Chronic Kidney Disease Japan Cohort (CKD-JAC) study. Nephrol Dial Transplant : doi : 10.1093/ndt/gfac134, 2022 (PMID : 35323977)
 
5) 富野康日己 : IgA 腎症診療指針 第2版. 日腎会誌, 44 : 487-493, 2002
 
6) Cattran DC, et al : The Oxford classification of IgA nephropathy : rationale, clinicopathological correlations, and classification. Kidney Int, 76 : 534-545, 2009 (PMID : 19571791)
 
7) Hotta O, et al : Limitation of kidney biopsy in detecting crescentic lesions in IgA nephropathy. Nephron, 65 : 472-473, 1993 (PMID : 8290004)
 
8) Tsuboi N, et al : Glomerular density in renal biopsy specimens predicts the long-term prognosis of IgA nephropathy. Clin J Am Soc Nephrol, 5 : 39-44, 2010 (PMID : 19965542)
 
9) Tsuboi N, et al : Changes in the glomerular density and size in serial renal biopsies during the progression of IgA nephropathy. Nephrol Dial Transplant, 24 : 892-899, 2009 (PMID : 18922859)
 
10) Tsuboi N, et al : Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy. Nephrol Dial Transplant, 26 : 3555-3560, 2011 (PMID : 21771759)
 
11) Bataille S, et al : Comparative safety and efficiency of five percutaneous kidney biopsy approaches of native kidneys : a multicenter study. Am J Nephrol, 35 : 387-393, 2012 (PMID : 22508466)
 
12) Simard-Meilleur MC, et al : Risk factors and timing of native kidney biopsy complications. Nephron Extra, 4 : 42-49, 2014 (PMID : 24803920)
 
13) Sonoda K, et al : Relationship between glomerular number in fresh kidney biopsy samples and light microscopy samples. Clin Exp Nephrol, 26 : 424-434, 2022 (PMID : 35103876)
 
14) Tondel C, et al : Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clin J Am Soc Nephrol, 7 : 1591-1597, 2012 (PMID : 22837269)
 
15) Chikamatsu Y, et al : Quantification of bleeding volume using computed tomography and clinical complications after percutaneous renal biopsy. Clin Kidney J, 10 : 9-15, 2017 (PMID : 28638600)
 
16) 河本順子 : 腎生検後血腫の超音波断層法による診断. 日腎会誌, 28 : 821-828, 1986
 
17) Ishikawa E, et al : How long is strict bed rest necessary after renal biopsy? Clin Exp Nephrol, 13 : 594-597, 2009 (PMID : 19578930)
 
18) Takeuchi Y, et al : Manual compression and reflex syncope in native renal biopsy. Clin Exp Nephrol, 22 : 1100-1107, 2018 (PMID : 29542049)
 
19) 沈載紀, 他 : 腎生検施行時における止血薬投与中止による出血への影響-腎生検にアドナ(R) は必要か. 日腎会誌, 62 : 45-51, 2020
 
20) Ishikawa E, et al : Ultrasonography as a predictor of overt bleeding after renal biopsy. Clin Exp Nephrol, 13 : 325-331, 2009 (PMID : 19381759)
 
21) Kawaguchi T, et al : A nationwide survey on clinical practice patterns and bleeding complications of percutaneous native kidney biopsy in Japan. Clin Exp Nephrol, 24 : 389-401, 2020 (PMID : 32189101)
 
22) 「腎生検ガイドブック 2020」 (一般社団法人日本腎臓学会/編) 東京医学社, 2020
 

17 ベストな血液透析導入のタイミング

P.203 掲載の参考文献
1) 花房規男, 他 : わが国の慢性透析療法の現況 (2020年12月31日現在). 日透析医会誌, 54 : 611-657, 2021
 
2) Nakayama M, et al : Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy : the Gonryo study. Hypertens Res, 34 : 1106-1110, 2011 (PMID : 21796127)
 
3) Isakova T, et al : Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int, 79 : 1370-1378, 2011 (PMID : 21389978)
 
4) Juurlink DN, et al : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med, 351 : 543-551, 2004 (PMID : 15295047)
 
5) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 341 : 709-717, 1999 (PMID : 10471456)
 
6) Kuczera P, et al : The Prevalence of Metabolic Acidosis in Patients with Different Stages of Chronic Kidney Disease : Single-Centre Study. Kidney Blood Press Res, 45 : 863-872, 2020 (PMID : 33070125)
 
7) Takaichi K, et al : The clinically significant estimated glomerular filtration rate for hyperkalemia. Intern Med, 47 : 1315-1323, 2008 (PMID : 18628579)
 
8) 日本透析医学会 : 維持血液透析ガイドライン (血液透析導入). 日透析医会誌, 46 : 1107-1155, 2013
 
9) Cooper BA, et al : A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med, 363 : 609-619, 2010 (PMID : 20581422)
 
10) Fu EL, et al : Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease : nationwide cohort study. BMJ, 375 : e066306, 2021 (PMID : 34844936)
 
11) Sato H, et al : Risk of cardiovascular mortality predicted by the serum calcium level and calcification score at the initiation of dialysis. Clin Exp Nephrol, 22 : 957-966, 2018 (PMID : 29302867)
 
12) Sato H, et al : Pre-Dialysis Neutrophil-Lymphocyte Ratio, a Novel and Strong Short-Term Predictor of All-Cause Mortality in Patients With Diabetic Nephropathy : Results From a Single-Center Study. Ther Apher Dial, 21 : 370-377, 2017 (PMID : 28665535)
 
13) Murea M, et al : Narrative Review of Incremental Hemodialysis. Kidney Int Rep, 5 : 135-148, 2020 (PMID : 32043027)
 
14) Murea M, et al : Twice-Weekly Hemodialysis With Adjuvant Pharmacotherapy and Transition to Thrice-Weekly Hemodialysis : A Pilot Study. Am J Kidney Dis : doi : 10.1053/j.ajkd.2021.12.001, 2021 (PMID : 34933066)
 
15) Vilar E, et al : A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function. Kidney Int, 101 : 615-625, 2022 (PMID : 34418414)
 
16) Nakao T, et al : Once-weekly hemodialysis combined with low-protein and low-salt dietary treatment as a favorable therapeutic modality for selected patients with end-stage renal failure : a prospective observational study in Japanese patients. BMC Nephrol, 19 : 151, 2018 (PMID : 29954331)
 
17) Nakai S, et al : An overview of regular dialysis treatment in Japan (as of 31 December 2012). Ther Apher Dial. 18 : 535-602, 2014 (PMID : 25523509)
 

書評

最近チェックした商品履歴

Loading...